Pharmacological effects on sympathetic tonus and heart rate in cardiovascular disease

被引：0

作者：

Zagidullin, N. Sh. ^{[1
]}

Zagidullin, Sh. Z. ^{[1
]}

机构：

[1] Bashkir State Med Univ, Ufa, Bashkir Rep, Russia

来源：

CARDIOVASCULAR THERAPY AND PREVENTION | 2009年 / 8卷 / 02期

关键词：

Sympathetic autonomous system; heart rate; heart rate regulation; cardiovascular mortality; pharmacotherapy; CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; I-F INHIBITOR; STABLE ANGINA; BLOOD-PRESSURE; RISK-FACTOR; VERAPAMIL; ATHEROSCLEROSIS; HYPERTENSION; IVABRADINE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recently, one of the leading approaches in the management of arterial hypertension (AH) and coronary heart disease (CHD) is reduction of sympathetic activity and one of its markers, heart rate (HR). HR is known as ail independent predictor of cardiovascular risk. At present, there are three main groups of the medications modulating sympathetic activity: beta-adrenoblockers (BAB), I-f channel inhibitors, and calcium antagonists, mostly dihydropyridine-type ones (verapamil SR). In contrast to BAB, verapamil SR combines moderate reduction in HR and sympathetic tonus with high antihypertensive and anti-anginal activity and minimal adverse effects. Therefore, verapamil SR is a medication of choice in AH and CHD treatment.

引用

页码：89 / 94

页数：6

共 29 条

[1] ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AND CALCIUM-ANTAGONISTS ALONE OR COMBINED - DOES THE PROGRESSION OF DIABETIC RENAL-DISEASE DIFFER [J].

BAKRIS, GL ;

WILLIAMS, B .

JOURNAL OF HYPERTENSION, 1995, 13 :S95-S101

[2] Influence of heart rate on mortality in a French population - Role of age, gender, and blood pressure [J].

Benetos, A ;

Rudnichi, A ;

Thomas, F ;

Safar, M ;

Guize, L .

HYPERTENSION, 1999, 33 (01) :44-52

[3] Heart rate-lowering and -regulating effects of once-daily sustained-release diltiazem [J].

Boden, WE ;

Vray, M ;

Eschwege, E ;

Lauret, D ;

Scheldewaert, R .

CLINICAL CARDIOLOGY, 2001, 24 (01) :73-79

[4] Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina -: A randomized, double-blind, multicentered, placebo-controlled trial [J].

Borer, JS ;

Fox, K ;

Jaillon, P ;

Lerebours, G .

CIRCULATION, 2003, 107 (06) :817-823

[5]

COHN JN, 1988, NEW ENGL J MED, V311, P819

[6]

DARDIE HJ, 1996, EUR HEART J, V17, P104

[7]

DECHAMPLAIN J, 1994, J HYPERTENS, V73, pC18

[8]

DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455

[9]

FARINARO E, 1995, ANN ITAL MED INT, V10, P31

[10] Guidelines on the management of stable angina pectoris: executive summary [J].

Fox, Kim ;

Angeles Alonso Garcia, Maria ;

Ardissino, Diego ;

Buszman, Pawel ;

Katowice ;

Camici, Paolo G. ;

Crea, Filippo ;

Daly, Caroline ;

De Backer, Guy ;

Ghent ;

Hjemdahl, Paul ;

Lopez-Sendon, Jose ;

Marco, Jean ;

Morais, Joao ;

Leiria ;

Pepper, John ;

Sechtem, Udo ;

Simoons, Maarten ;

Thygesen, Kristian ;

Priori, Silvia G. ;

Blanc, Jean-Jacques ;

Budaj, Andrzej ;

Camm, John ;

Dean, Veronica ;

Deckers, Jaap ;

Dickstei, Kenneth ;

Lekakis, John ;

McGregor, Keith ;

Metra, Marco ;

Morais, Joao ;

Osterspey, Ady ;

Tamargo, Juan ;

Zamorano, Jose L. ;

Andreotti, Felicita ;

Becher, Harald ;

Dietz, Rainer ;

Fraser, Alan ;

Hernandez Antolin, Rosa Ana ;

Huber, Kurt ;

Kremastinos, Dimitris T. ;

Maseri, Attilio ;

Nesser, Hans-Joachim ;

Pasierski, Tomasz ;

Sigwart, Ulrich ;

Tubaro, Marco ;

Weis, Michael .

EUROPEAN HEART JOURNAL, 2006, 27 (11) :1341-1381

← 1 2 3 →